Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosmanogepix (APX001) for Invasive Mold Infections
NCT04240886Phase 2Terminated
- Sponsor
- Basilea Pharmaceutica
- Start
- Jan 2020
- Primary completion
- Mar 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of fosmanogepix in invasive aspergillosis (IA), scedosporiosis, fusariosis, mucormycosis, sponsored by Basilea Pharmaceutica. Started Jan 2020; status: terminated.
02
Drugs
fosmanogepix
03
Conditions
invasive aspergillosis (IA)scedosporiosisfusariosismucormycosis
Beyond the preview
Go deeper on NCT04240886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04240886.